BioNTech SE (WBO:BNTX) EBIT : €924 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE EBIT?

BioNTech SE's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was €377 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €924 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioNTech SE's annualized ROC % for the quarter that ended in Dec. 2023 was 29.31%. BioNTech SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 84.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioNTech SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 28.34%.

BioNTech SE EBIT Historical Data

The historical data trend for BioNTech SE's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE EBIT Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-177.70

-143.80

14,927.10

12,303.80

904.20

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															2,505.50	729.00	-410.90	229.40	376.80

Competitive Comparison of BioNTech SE's EBIT

For the Biotechnology subindustry, BioNTech SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioNTech SE's EV-to-EBIT falls into.

BioNTech SE EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €924 Mil.

BioNTech SE (WBO:BNTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioNTech SE's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	2392 * ( 1 - 30.96% )	/	( (5690.2	+	5577.8)	/ 2 )
=	1651.4368	/	5634
=	29.31 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22207.2	-	767.9	-	( 15749.1	-	max(0, 1807.2	-	18749.1	+	15749.1	))
=	5690.2

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	23006.3	-	879.5	-	( 16549	-	max(0, 2070.5	-	19527.3	+	16549	))
=	5577.8

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

BioNTech SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1507.2	/	( ( (925.9 + max(936.7, 0))	+	(971.6 + max(751.9, 0)) )	/	2 )
=	1507.2	/	( ( 1862.6	+	1723.5 )	/	2 )
=	1507.2	/	1793.05
=	84.06 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2002	+	415.7	+	286.2)	-	(767.9	+	167.1	+	832.2)
=	936.7

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2155.7	+	357.7	+	280.9)	-	(879.5	+	353.3	+	809.6)
=	751.9

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioNTech SE's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	924.3	/	3261.418
	=	28.34 %

BioNTech SE EBIT Related Terms

Thank you for viewing the detailed overview of BioNTech SE's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (WBO:BNTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.